BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31812631)

  • 1. SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States.
    Khanani AM; Skelly A; Bezlyak V; Griner R; Torres LR; Sagkriotis A
    Ophthalmol Retina; 2020 Feb; 4(2):122-133. PubMed ID: 31812631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
    Ciulla TA; Hussain RM; Pollack JS; Williams DF
    Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.
    Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
    Ophthalmology; 2014 May; 121(5):1092-101. PubMed ID: 24461586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
    Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
    Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade.
    Schwartz R; Warwick A; Olvera-Barrios A; Pikoula M; Lee AY; Denaxas S; Taylor P; Egan C; Chakravarthy U; Lip PL; Tufail A;
    Ophthalmol Retina; 2021 Aug; 5(8):e11-e22. PubMed ID: 33866023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource.
    Fasler K; Moraes G; Wagner S; Kortuem KU; Chopra R; Faes L; Preston G; Pontikos N; Fu DJ; Patel P; Tufail A; Lee AY; Balaskas K; Keane PA
    BMJ Open; 2019 Jun; 9(6):e027441. PubMed ID: 31230012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence.
    Chakravarthy U; Bezlyak V; Sagkriotis A; Griner R; Skelly A; Boyer DS; Milnes F
    Ophthalmol Retina; 2019 Jan; 3(1):8-15.e1. PubMed ID: 30929819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
    Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
    Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients.
    Johnston RL; Lee AY; Buckle M; Antcliff R; Bailey C; McKibbin M; Chakravarthy U; Tufail A;
    Ophthalmology; 2016 Nov; 123(11):2386-2392. PubMed ID: 27615601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.
    Fasler K; Fu DJ; Moraes G; Wagner S; Gokhale E; Kortuem K; Chopra R; Faes L; Preston G; Pontikos N; Patel PJ; Tufail A; Lee AY; Balaskas K; Keane PA
    Br J Ophthalmol; 2020 May; 104(5):684-690. PubMed ID: 31611234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Nguyen CL; Gillies MC; Nguyen V; Daien V; Cohn A; Banerjee G; Arnold J;
    Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
    Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration.
    Chandra S; Arpa C; Menon D; Khalid H; Hamilton R; Nicholson L; Pal B; Fasolo S; Hykin P; Keane PA; Sivaprasad S
    Eye (Lond); 2020 Oct; 34(10):1888-1896. PubMed ID: 31980748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
    Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
    Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register.
    Westborg I; Granstam E; Rosso A; Albrecht S; Karlsson N; Lövestam-Adrian M
    Acta Ophthalmol; 2017 Dec; 95(8):787-795. PubMed ID: 28834299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany].
    Ziemssen F; Eter N; Fauser S; Bopp S; Radermacher M; Hasanbasic Z; Holz FG;
    Ophthalmologe; 2015 Mar; 112(3):246-54. PubMed ID: 25668709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Incremental and Future Visual Change in Neovascular Age-Related Macular Degeneration Using Deep Learning.
    Fu DJ; Faes L; Wagner SK; Moraes G; Chopra R; Patel PJ; Balaskas K; Keenan TDL; Bachmann LM; Keane PA
    Ophthalmol Retina; 2021 Nov; 5(11):1074-1084. PubMed ID: 33516917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.